Dr. Reddy's Q1FY27 Earnings Call Transcript Released; Revenue Declines 5.6%
Dr. Reddy's Q1FY27 consolidated revenue declined 5.6% YoY to ₹8,071 crores, impacted by lower lenalidomide sales and a ₹240 crore provision for semaglutide API issues. Underlying base business showed double-digit growth. EBITDA margin was 12.5%, expected to improve with semaglutide resumptions in November 2026.
The revenue decline and provisions are material, impacting current financial performance. However, the strong base business growth and plans for semaglutide resumptions suggest a medium-term recovery potential.
The company reported a revenue decline and significant provisions impacting profitability, but also highlighted strong underlying base business growth and a clear plan for product resumptions, leading to a neutral sentiment.
Dr. Reddy's Laboratories Limited has released the transcript of its Earnings Call for the quarter ended June 30, 2026, which was conducted on July 22, 2026. The company reported consolidated revenues of ₹8,071 crores (US$853 million), a year-on-year decline of 5.6%, attributed primarily to lower lenalidomide sales and a provision of ₹240 crores for semaglutide API-related challenges.
Despite the overall revenue decline, the underlying base business demonstrated healthy double-digit growth across key geographies, including North America, supported by new product launches and favorable currency movements. The SG&A spend increased by 12% YoY to ₹2,882 crores, and R&D spend was ₹577 crores, down 8% YoY. The underlying EBITDA margin for the quarter was 12.5%, impacted by the semaglutide provision and higher solvent costs due to the Middle East conflict. Excluding this provision, the margin was 15.4%.
Erez Israeli, CEO, highlighted the company's focus on strategic priorities, including strengthening base businesses and building growth engines in peptides, biosimilars, and consumer health. He noted that excluding the semaglutide-related impacts and the Middle East conflict, the EBITDA margin would have been in the high teens (around 18%). The company plans to resume semaglutide commercial supplies by November 2026. Key business highlights included the commercialization of complex generics like bosutinib and nintedanib in the US, and the launch of oral semaglutide in India. The company also made progress on in-licensed therapies and partnerships.
Regarding the US FDA inspection at the Bachupally facility, seven observations were issued, to which the company has responded. The BLA goal date for abatacept remains in December 2026. The company maintained its guidance for a normalized tax rate of 24-25% and R&D spend of 7-8% of revenues. The projected CAPEX for the full year is around ₹1,800 crores.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.